TarunKewalramaniMD

Hematology • Burlington, MA

Vice chair for Hematology, Division of Hematology/Oncology- Lahey Hospital and Medical Center Associate Professor, Medicine, Tufts Medical Center

Join to view full profile

Dr. Kewalramani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kewalramani's full profile

Already have an account?

Office
41 Mall Rd
Lahey Hospital and Medical Center
Burlington, MA 01805
Phone+1 781-744-8400

Fax+1 781-744-5245
Is this information wrong?

Summary

Dr. Tarun Kewalramani is a hematologist in Burlington, MA and is affiliated with Lahey Hospital & Medical Center, Burlington. He received his medical degree from McGaw Medical Center of Northwestern University and has been in practice 22 years.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
Boston University Medical CenterResidency, Internal Medicine, 1995 - 1998
Northwestern University The Feinberg School of MedicineClass of 1995

Certifications & Licensure

MA State Medical License 1997 - 2024
MA State Medical License 1995 - 2024
NY State Medical License 1998 - 2009
American Board of Internal Medicine Hematology

Clinical Trials

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma Start of enrollment: 2003 Jan 01
Completed
Phase 2
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3

Publications & Presentations

PubMed

1 citations
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted appro...
Oscar B Lahoud, Heather Landau, James Nguyen, Sean Devlin, Nikoletta Lendvai, Jonathan Weltz, Tumininu Ayorinde, David J Chung, Alexander M Lesokhin, Tarun Kewalramani...> ;Leukemia & Lymphoma. 2022 Sep 1
9 citations
Acute Myeloid Leukemia After Radium-223 Therapy: Case Report.
Andreas Varkaris, Krishna S Gunturu, Tarun Kewalramani, Christopher Tretter> ;Clinical Genitourinary Cancer. 2017 Aug 1
302 citations
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer, Carol S. Portlock, David J. Straus, Ariela Noy, Owen A. O'Connor, Daniel A. Filippa, Julie Teruya-Feldstein, A...> ;Blood. 2004 May 15
37 citations
Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.
Hans G. Klingemann, Carrie Grodman, Elliott Cutler, Marvin Duque, Diane Kadidlo, Andreas K. Klein, Kellie Sprague, Kenneth B. Miller, Raymond L. Comenzo, Tarun Kewalra...> ;Transfusion. 2013 Feb 1
46 citations
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga, Donald S. Gravenor, Dipti Patel-Donnelly, Robert S. Siegel, Tarun Kewalramani, Edward...> ;British Journal of Haematology. 2013 Feb 1
Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial.
Berenson JR, Yellin O, Bessudo A, Boccia R, Noga S, Gravenor D, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Swift R, Bensen-Kennedy D> ;J. Clin. Oncol.. 2011-05-20
17 citations
Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients
Sherry Mathew, Nelly G. Adel, R.D. Rice, Katherine S. Panageas, Elaine Duck, Raymond L. Comenzo, Tarun Kewalramani, Stephen D. Nimer> ;Bone Marrow Transplantation. 2010 Oct 1
181 citations
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
Alison J. Moskowitz, Joachim Yahalom, Tarun Kewalramani, Jocelyn C. Maragulia, Jill M. Vanak, Andrew D. Zelenetz, Craig H. Moskowitz> ;Blood. 2010 Dec 2
66 citations
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
Craig H. Moskowitz, Joachim Yahalom, Andrew D. Zelenetz, Zhigang Zhang, Daniel A. Filippa, Julie Teruya-Feldstein, Tarun Kewalramani, Alison J. Moskowitz, R.D. Rice, J...> ;British Journal of Haematology. 2010 Mar 1
19 citations
Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.
M.-A. Perales, Robert R. Jenq, Jenna D. Goldberg, Andrew Wilton, Sinda S. Lee, Hugo Castro-Malaspina, Katharine C. Hsu, Esperanza B. Papadopoulos, M.R.M. van den Brink...> ;Bone Marrow Transplantation. 2010 Jan 11
122 citations
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
Alison J. Moskowitz, Miguel-Angel Perales, Tarun Kewalramani, Joachim Yahalom, Hugo Castro-Malaspina, Zhigang Zhang, Jill M. Vanak, Andrew D. Zelenetz, Craig H. Moskowitz> ;British Journal of Haematology. 2009 Jul 1
Phase II trial of temozolomide (TMZ) followed by myeloablative chemotherapy with autologous peripheral blood progenitor cell rescue (APBPCR) for newly diagnosed anapla...
Kaley TJ, Raizer JJ, Paleologos N, Kewalramani T, Grimm S, Louis DN, Cairncross JG, Abrey LE> ;J. Clin. Oncol.. 2009-05-20
Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF> ;J. Clin. Oncol.. 2009-05-20
338 citations
American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
Martee L. Hensley, Karen L. Hagerty, Tarun Kewalramani, Daniel M. Green, Neal J. Meropol, Todd H. Wasserman, Gary I. Cohen, Bahman Emami, William J. Gradishar, R. Bria...> ;Journal of Clinical Oncology. 2009 Jan 1
43 citations
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
Hani Hassoun, Carlos D. Flombaum, Vivette D. D'Agati, B T Rafferty, Adam D. Cohen, Virginia M. Klimek, Adam Boruchov, Tarun Kewalramani, L Reich, Stephen D. Nimer, Ray...> ;Bone Marrow Transplantation. 2008 Jun 23
12 citations
Reversible Fanconi syndrome due to lenalidomide
Ilya G. Glezerman, Tarun Kewalramani, Kenar D. Jhaveri> ;NDT Plus. 2008 Aug 1
8 citations
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis
Nimish Mohile, Peter A. Forsyth, Douglas A. Stewart, Jeffrey J. Raizer, Nina Paleologos, Tarun Kewalramani, David N. Louis, J. Gregory Cairncross, Lauren E. Abrey> ;Journal of Neuro-Oncology. 2008 May 6
31 citations
Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity
Bradford S. Hoppe, Craig H. Moskowitz, Daniel A. Filippa, Chaya S. Moskowitz, Tarun Kewalramani, Andrew D. Zelenetz, Joachim Yahalom> ;Journal of Clinical Oncology. 2008 Apr 10
85 citations
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Adam D. Cohen, Ping Zhou, Joanne Chou, Julie Teruya-Feldstein, Lilian Reich, Hani Hassoun, Beth Levine, Daniel A. Filippa, Elyn Riedel, Tarun Kewalramani, Michael D. S...> ;British Journal of Haematology. 2007 Oct 1
85 citations
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
Tarun Kewalramani, Andrew D. Zelenetz, Julie Teruya-Feldstein, Paul A. Hamlin, Joachim Yahalom, Steven M. Horwitz, Stephen D. Nimer, Craig H. Moskowitz> ;British Journal of Haematology. 2006 Jul 1
8 citations
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Raymond L. Comenzo, Hani Hassoun, Tarun Kewalramani, Virginia M. Klimek, L Reich, Julie Teruya-Feldstein, Martin Fleisher, Daniel A. Filippa, Stephen D. Nimer> ;Leukemia. 2006 Feb 1
1 citations
The serum IL-12:IL-6 ratio reliably distinguishes infectious from non-infectious causes of fever during autologous stem cell transplantation
Roman A. Tuma, Nikolaos G. Almyroudis, S. J. Sohn, Katherine S. Panageas, R.D. Rice, D. Galinkin, M. Blain, M. Montefusco, Eric G. Pamer, Stephen D. Nimer, Tarun Kewal...> ;Cytotherapy. 2006 Jan 1
32 citations
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
Hani Hassoun, Lilian Reich, Virginia M. Klimek, Adam D. Cohen, Tarun Kewalramani, Rachel Zimman, Lisa Drake, Elyn Riedel, Cyrus V. Hedvat, Julie Teruya-Feldstein, Dani...> ;British Journal of Haematology. 2006 Jan 1
65 citations
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with re...
Craig H. Moskowitz, Andrew D. Zelenetz, Tarun Kewalramani, Paul A. Hamlin, Simone Lessac-Chenen, Jane Houldsworth, Adam B. Olshen, R. S. K. Chaganti, Stephen D. Nimer,...> ;Blood. 2005 Nov 15
14 citations
Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
, , , , , , , , , , , , , , , > ;Bone Marrow Transplantation. 2005 Mar 1
Join now to see all

Professional Memberships

American Society of Hematology - ASH
Member

Hospital Affiliations

Lahey Hospital & Medical CenterBurlington, Massachusetts